For instance, Insulet's Omnipod, a tubeless and waterproof Automated Insulin Delivery (AID) system, works alongside a glucose sensors to automatically adjust basal insulin levels according to continuous glucose readings.
According to the survey conducted by OnePoll for Insulet, 91% of Multiple Daily Injections (MDI) users would likely be interested in technology that could minimise or eliminate their need for daily injections.
Despite the high level of interest, data from Seagrove suggests that only 24% of people with Type 1 Diabetes (T1D) in Europe currently utilise advanced systems like automated insulin delivery.
Multiple daily injections (MDI) continue to be the most prevalent method of managing T1D, but this strategy can also negatively affect quality of life according to the study.
T1D, a condition where the body's insulin production is compromised, affects the daily routines of those diagnosed, with nearly a third admitting it influences their everyday choices.
